Our goal is to make biological drugs accessible

Biological drugs have revolutionized the treatment of many serious diseases such as cancer, rheumatoid arthritis, psoriasis and macular degeneration. The only problem is that they are so expensive that only a fraction of those affected can be treated with them. Our goal is to make biological drugs accessible to everyone who needs them.

We strive towards the lowest possible production cost

We base the development of our Biosimilars on the patented platform technology that can provide up to 12 times productivity and thereby up to an 80% cost reduction compared to standard systems in the development of biological drugs.

We are building a world-leading biosimilar developer

We develop biosimilars in treatment of macular degeneration ( Xlucane™), rheumatoid arthritis and psoriasis (Xcimzane ™) and cancer (Xdivane™) addressing originator sales of over SEK 100 billion




Patents and patent applications


Biosimilars under development

Capital Markets Day 17 May, 2021

At Xbrane Biopharma

Press Releases

18 Jan 2022

Xbrane Biopharma changes the date for Interim and Year-end Report

20 Dec 2021

Xbrane Biopharma moves to Nasdaq Stockholm Mid Cap segment

13 Dec 2021

Xbrane has initiated development of two new biosimilar candidates, building an oncology biosimilar portfolio targeting €23 billion in annual reference product sales

29 Oct 2021

Xbrane Biopharma releases interim report for January – September 2021

28 Oct 2021

Invitation to presentation of Xbrane Biopharma’s interim report January – September, 2021 on October 29, 2021.

27 Oct 2021

Xbrane announces four more patents granted

18 Oct 2021

Xbrane Biopharma presents Nomination Committee

11 Oct 2021

Xbrane announces two granted patents that strengthens its high yield protein expression platform

07 Oct 2021

Xbrane Biopharma and AGC Biologics enter into an Agreement to Manufacture Xcimzane™ for Clinical Development